Defining optimal tracer activities in pediatric oncologic whole-body 18F-FDG-PET/MRI
- 26 August 2016
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 43 (13) , 2283-2289
Abstract
Purpose To explore the feasibility of reducing administered tracer activities and to assess optimal activities for combined 18F-FDG-PET/MRI in pediatric oncology. Methods 30 18F-FDG-PET/MRI examinations were performed on 24 patients with known or suspected solid tumors (10 girls, 14 boys, age 12 ± 5.6 [1–18] years; PET scan duration: 4 min per bed position). Low-activity PET images were retrospectively simulated from the originally acquired data sets using randomized undersampling of list mode data. PET data of different simulated administered activities (0.25–2.5 MBq/kg body weight) were reconstructed with or without point spread function (PSF) modeling. Mean and maximum standardized uptake values (SUVmean and SUVmax) as well as SUV variation (SUVvar) were measured in physiologic organs and focal FDG-avid lesions. Detectability of organ structures and of focal 18F-FDG-avid lesions as well as the occurrence of false-positive PET lesions were assessed at different simulated tracer activities. Results Subjective image quality steadily declined with decreasing tracer activities. Compared to the originally acquired data sets, mean relative deviations of SUVmean and SUVmax were below 5 % at 18F-FDG activities of 1.5 MBq/kg or higher. Over 95 % of anatomic structures and all pathologic focal lesions were detectable at 1.5 MBq/kg 18F-FDG. Detectability of anatomic structures and focal lesions was significantly improved using PSF. No false-positive focal lesions were observed at tracer activities of 1 MBq/kg 18F-FDG or higher. Administration of 18F-FDG activities of 1.5 MBq/kg is, thus, feasible without obvious diagnostic shortcomings, which is equivalent to a dose reduction of more than 50 % compared to current recommendations. Conclusion Significant reduction in administered 18F-FDG tracer activities is feasible in pediatric oncologic PET/MRI. Appropriate activities of 18F-FDG or other tracers for specific clinical questions have to be further established in selected patient populations.Keywords
Funding Information
- Siemens (DE)
This publication has 18 references indexed in Scilit:
- Simultaneous Whole-Body PET/MR Imaging in Comparison to PET/CT in Pediatric Oncology: Initial ResultsRadiology, 2014
- Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort studyThe Lancet, 2012
- MRI-Based Attenuation Correction for Whole-Body PET/MRI: Quantitative Evaluation of Segmentation- and Atlas-Based MethodsJournal of Nuclear Medicine, 2011
- Additional Benefit of F-18 FDG PET/CT in the Staging and Follow-up of Pediatric RhabdomyosarcomaClinical Nuclear Medicine, 2011
- Evaluation of Optimal Acquisition Duration or Injected Activity for Pediatric 18F-FDG PET/CTJournal of Nuclear Medicine, 2011
- Estimated cumulative radiation dose from PET/CT in children with malignancies: a 5-year retrospective reviewPediatric Radiology, 2009
- Weight-Based, Low-Dose Pediatric Whole-Body PET/CT ProtocolsJournal of Nuclear Medicine, 2009
- Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncologyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Positron Emission Tomography for Staging of Pediatric Sarcoma Patients: Results of a Prospective Multicenter TrialJournal of Clinical Oncology, 2007
- 18F-FDG PET in children with lymphomasEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004